Male Breast Cancer: A Single Center Case Series
Judi Clinical Journal · 2025
DOI: 10.70955/jcj.2025.11 ↗Kurz gefasst
Fachartikel in der Zeitschrift Judi Clinical Journal, 2025. Verfasst von Abdulwahid M. Salih und 15 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Male breast cancer is a rare malignancy, and despite increasing its prevalence, little is known about its prognosis, and management continues to rely largely on guidelines developed for female breast cancer. This study presents a single-center experience focusing on the diagnosis, therapeutic strategies, and prognostic outcomes associated with male breast cancer.
Methods
The study was carried out between May 2020 and January 2025. All the male patients diagnosed with breast cancer were identified from the center's database. The study included those with complete medical records, encompassing demographics, clinical presentation, imaging findings, outcome, and follow-up data.
Results
Fifteen male breast cancer cases were analyzed (mean age 59.47 ± 12.97 years). The left breast was affected in 60%, and 80% presented with a painless lump. Tumor size ranged 0.6–5.4 cm (mean 2.53 ± 1.50 cm). Modified radical mastectomy was performed in 86.66%. Invasive ductal carcinoma predominated (93.33%), with lymph node involvement in 40% and bone metastasis in 6.67%. Immunohistochemistry results were available for 5 patients (33.33%); all of them were estrogen receptor and progesterone receptor positive and human epidermal growth factor receptor 2 negative. Adjuvant chemotherapy and radiotherapy were used in 33.33%, while 20% received triple modality therapy. Mean follow-up was 2.8 ± 1.52 years (range 1–5), with one recurrence.
Conclusion
Male breast cancer may present as a breast mass and is often diagnosed as invasive ductal carcinoma. Modified radical mastectomy accompanied by adjuvant therapy might offer favorable outcomes.
Introduction
Male breast cancer (MBC) is a rare condition, representing about 1% of all malignancies in men and of all breast cancer cases globally. Moreover, MBC accounts for less than 0.2% of cancer-related mortality among men. Breast cancer occurs less frequently in males, with a male-to-female ratio of approximately 1:100. This lower incidence is primarily attributed to the limited amount of breast tissue and differences in hormonal profiles between men and women [1-3]. Data from the Surveillance, Epidemiology, and End Results (SEER) program show an increase in male breast cancer incidence from 1.0 per 100,000 in the late 1970s to 1.2 per 100,000 in 2000–2004, with a median age at diagnosis of 67 years [2,4]. Like female patients, certain germline mutations increase the risk of breast and other cancers in men. Approximately 15% to 20% of men with breast cancer report a family history of breast or ovarian cancer, and around 10% carry a known hereditary mutation associated with breast cancer predisposition. BRCA2 is the gene most strongly associated with MBC, with affected individuals facing a lifetime risk ranging from 1% to 6%, higher than the approximate 0.1% risk in the general male population [4]. Additional genetic risk factors may contribute to the development of MBC, such as alterations in the ratio of estrogen to testosterone, as seen in individuals with Klinefelter syndrome [5]. Management of MBC is largely adapted from treatment protocols established for female breast cancer (FBC), owing to the limited availability of prospective, male-specific clinical trials. Notably, male patients represented only 0.087% of participants across 131 breast cancer clinical trials [6]. The current study presents a single-center experience regarding the diagnosis, management, and prognosis of MBC patients. All the references have been evaluated, and non-peer-reviewed sources have been excluded [7].
Methods
Study Design and Setting This study was a single-center case series carried out at the Breast Clinic of Smart Health Tower between May 2020 and January 2025. This study was approved by the Ethics Committee of Kscien organization (Approval No. 2025-36). Participants and Eligibility Criteria The study included patients with a confirmed histopathological diagnosis of MBC who had complete medical records and provided consent for the publication of their data. Data Collection Data were retrieved from the hospital’s registry. The parameters included demographic details, clinical presentation, diagnostic findings, management, outcome, and follow-up.
Intervention
The patients underwent surgery under general anesthesia in the supine position, following skin preparation and antiseptic measures. The surgical approach was tailored to the specific requirements of each case, utilizing elliptical, Stewart, or alternative incision techniques as appropriate. After the incisions, procedures such as wide local excision, modified radical mastectomy (MRM), or nipple-areolar sparing mastectomy were performed. In all cases, the long thoracic and thoracodorsal nerves were preserved. Lymph node management involved either sampling or dissection of levels I, II, and III. Hemostasis was secured, and a Redivac drain was placed for each patient. Finally, the surgical site was closed in anatomical layers. For histopathology, 5-µm-thick tissue sections were fixed in 10% neutral buffered formalin at room temperature for 24 hours and subsequently embedded in paraffin. The slides were prepared and stained with hematoxylin and eosin (Bio Optica Co.) for 1–2 minutes at room temperature, then examined using a light microscope (Leica Microsystems GmbH). Data Processing and Statistical Analysis All collected data were recorded and organized using Microsoft Excel 2021. Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS), version 25.0. Descriptive statistics were applied to summarize the results. Continuous variables were reported as means with standard deviations or medians with interquartile ranges, while categorical variables were presented as frequencies and percentages.
Results
Patient Demography A total of 15 MBC cases were diagnosed and managed during the period of conducting the study. Ages ranged from 40 to 85 years (59.47 ± 12.97). All participants were manual workers. 1 patient (6.67%) was an active smoker, 1 (6.67%) was a passive smoker, and none reported alcohol consumption. The history of breast cancer was positive in 1 patient (6.67%) who had undergone mastectomy (Table 1). Table 1. Demographic Data and Patient History Variables Frequency (%) Age 40-49 50-59 60-69 >70 Mean ± SD 2 (13.33%) 8 (53.33%) 2 (13.33%) 3 (20.00%) 59.47 ± 12.97 Occupations Manual labor 15 (100%) Smoking status Active smoker Passive smoker Non-smoker 1 (6.67%) 1 (6.67%) 13 (86.66%) Medical history Breast cancer Hypertension Hypertension & diabetes mellitus Negative 1 (6.67%) 2 (13.33%) 1 (6.67%) 11 (73.33%) Surgical history Mastectomy Herniotomy PNS surgery Hemorrhoidectomy Laparoscopic cholecystectomy & eye surgery Negative 1 (6.67%) 2 (13.33%) 1 (6.67%) 1 (6.67%) 1 (6.67%) 9 (60.00%) Family history of breast cancer Positive Negative 1 (6.67%) 14 (93.33%) SD: standard deviation, PNS: pilonidal sinus Clinical Presentation and Diagnosis The left side was involved in 9 patients (60%), while the right side was affected in 6 patients (40%). Clinical presentations included a painless breast lump in 12 patients (80%) and an axillary lump, breast discharge, and breast pain in each of the remaining patients (6.67%). Gynecomastia was present in 2 cases (13.33%). The duration of symptoms ranged from one week to two years, with a median of 0.69 (5.77) months. On ultrasonography, tumor sizes ranged from 0.6 cm to 5.4 cm, with a mean size of 2.53 ± 1.50 cm. Tumors were located centrally in 10 patients (66.66%), in the upper outer quadrant in 3 patients (20%), and in the upper inner quadrant and axilla each in 1 patient (6.67%) (Table 2). Mammography was performed for 5 patients (33.33%), all of whom had microcalcifications with variations in margin appearance (Figure 1). Computed tomography revealed lymphadenopathy in 5 (33.33%) patients (Figure 2). Table 2. Clinical Findings of Male Breast Cancer patients Variable Frequency (%) Affected side Right Left 6 (40.00%) 9 (60.00%) Clinical presentation Painless breast lump Axillary lump Breast discharge Breast pain 12 (80.00%) 1 (6.67%) 1 (6.67%) 1 (6.67%) Presence of gynecomastia Yes No 2 (13.33%) 13 (86.67%) Duration of symptoms, months (median (IQR)) 0.69 (5.77) Tumor size (cm), mean ± SD 2.53 ± 1.50 Tumor location Central Upper outer quadrant Upper inner quadrant Axilla 10 (66.66%) 3 (20.00%) 1 (6.67%) 1 (6.67%) IQR: Interquartile range, cm: Centimeter, SD: Standard deviation Management and Outcome Thirteen patients (86.66%) underwent MRM. Of these, 6 patients (40%) had MRM with axillary sampling only, while 7 patients (46.66%) underwent MRM combined with axillary lymph node dissection (ALND) at different levels (5 cases with ALND levels I and II, one with ALND levels I, II, and III, and one with ALND level I). One case (6.67%) underwent bilateral nipple-areola sparing mastectomy with radiotherapy and axillary sampling. Additionally, wide local excision with axillary sampling was performed in one patient (6.67%) (Figures 3-5). Histopathology confirmed invasive ductal carcinoma (IDC) in 14 cases (93.33%), either in isolation or in association with other pathological findings (Figure 6). Seven patients (46.67%) had grade II tumors, while six patients (40.0%) had grade III tumors. Regarding lymph node status, 9 patients (60.0%) had no evidence of lymph node involvement, whereas 6 patients (40.0%) showed varying degrees of lymphatic spread. Bone metastasis was recorded in one patient (6.67%). Immunohistochemistry results were available for 5 patients (33.33%); all of them were estrogen receptor and progesterone receptor positive and HER2 negative. Ki-67 proliferation index was reported in 3 patients (20%), with values ranging from 40% to 41%. The most used adjuvant therapy included a combination of chemotherapy and radiotherapy in 5 cases (33.33%), and a combination of chemotherapy, radiotherapy, and hormonal treatment in 3 cases (20%). The follow-up period ranged from 1 to 5 years (2.8 ± 1.52 years), and only one case of recurrence was reported (Table 3). Table 3. Management and Follow-Up of Male Breast Cancer Patients Variables Frequency (%) Surgical approaches MRM & axilla sampling MRM + ALND WLE NASM 6 (40.00%) 7 (46.66%) 1 (6.67%) 1 (6.67%) Histopathological findings IDC of NST IDC of NST + DCIS IDC of NST with High Grade DCIS + Paget IDC of Papillary Type and Extensive DCIS High-grade sarcoma favoring undifferentiated pleomorphic sarcoma 7 (46.66%) 5 (33.33%) 1 (6.67%) 1 (6.67%) 1 (6.67%) Tumor grades Grade I (Well-differentiated) Grade II (Moderately differentiated) Grade III (Poorly differentiated) Grade IV (Undifferentiated) N/A 0 (0.00%) 7 (46.67%) 6 (40.00%) 0 (0.00%) 2 (13.33%) Immunohistochemical findings ER+/PR+/HER2- N/A 5 (33.33%) 10 (66.67%) Lymph node involvement No involvement Single node Multiple nodes 9 (60.00%) 4 (26.67%) 2 (13.33%) Distant metastasis Bones None 1 (6.67%) 14 (93.33%) Adjuvant therapy Chemotherapy & radiotherapy Radiotherapy & hormone therapy* Chemotherapy & radiotherapy & hormone therapy* Chemotherapy alone Radiotherapy alone Hormone therapy alone* No adjuvant therapy 5 (33.33%) 1 (6.67%) 3 (20.00%) 1 (6.67%) 1 (6.67%) 1 (6.67%) 3 (20.00%) Follow-up (years), mean ± SD 2.8 ± 1.52 Outcome Recurrence Remission 1 (6.67%) 14 (93.33%) MRM: modified radical mastectomy, ALND: axillary lymph node dissection, WLE: wide local excision, NASM: nipple-areolar sparing mastectomy, IDC: invasive ductal carcinoma, NST: non-specific type, DCIS: ductal carcinoma in situ, ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor 2, SD: standard deviation, N/A: not available. *Tamoxifen Discussion Breast cancer in males accounts for
Zitieren
APA
Salih, A. M., Pshtiwan, L. R., Fattah, F. H., Abdullah, A. M., Ali, R. M., Mohammed, R. O., Baba, H. O., Ahmed, A. H., Arif, S. O., Sabr, N. S., Hassan, S. H., Fatih, H. H., Ahmed, M. K., Abdulkarim, M. M., Abdullah, H. O., & Kakamad, F. H. (2025). Male Breast Cancer: A Single Center Case Series. Judi Clinical Journal. https://doi.org/10.70955/jcj.2025.11
Vancouver
Salih AM, Pshtiwan LR, Fattah FH, Abdullah AM, Ali RM, Mohammed RO, et al. Male Breast Cancer: A Single Center Case Series. Judi Clinical Journal. 2025. doi:10.70955/jcj.2025.11
BibTeX
@article{Salih2025,
author = {Salih, Abdulwahid M. and Pshtiwan, Lana RA. and Fattah, Fattah H. and Abdullah, Ari M. and Ali, Rebaz M. and Mohammed, Rebaz O. and Baba, Hiwa O. and Ahmed, Ahmed H. and Arif, Sakar O. and Sabr, Nasren S. and Hassan, Shko H. and Fatih, Harzal H. and Ahmed, Masty K. and Abdulkarim, Meer M. and Abdullah, Hiwa O. and Kakamad, Fahmi H.},
title = {Male Breast Cancer: A Single Center Case Series},
journal = {Judi Clinical Journal},
year = {2025},
doi = {10.70955/jcj.2025.11}
}
EUVIMED